Rosalind Advisors Inc's Q2 2026 13F: 3 new positions, 6 exits

Form 13F-HR for the quarter ended Jun 30, 2026 · filed Aug 14, 2026 · 29 reported positions · accession 0001622627-26-000022

What changed this quarter

Rosalind Advisors Inc's changes in reported equity positions, Q2 2026
Activity Security Weight before Weight now Change Shares Shares %
Exited CG ONCOLOGY INC (CGON) 2.8% — −2.8 pts −100K sh −100%
Increased VERASTEM INC (VSTM) 4.6% 5.7% +1.1 pts +1.85M sh +86%
Exited VIRIDIAN THERAPEUTICS INC (VRDN) 2.0% — −2.0 pts −250K sh −100%
Reduced VAXCYTE INC (PCVX) 6.9% 4.4% −2.5 pts −90,000 sh −31%
Reduced CELLDEX THERAPEUTICS INC (CLDX) 4.3% 2.8% −1.5 pts −130K sh −39%
Increased FENNEC PHARMACEUTICALS INC (FENC) 7.3% 12.9% +5.5 pts +280K sh +10%
Increased CYBIN INC (CYBN) 3.0% 4.9% +1.8 pts +425K sh +28%
New ABIVAX SA (ABVX) — 1.0% +1.0 pts +20,869 sh new
Exited DEFINIUM THERAPEUTICS INC (DFTX) 1.0% — −1.0 pts −125K sh −100%
Reduced XERIS BIOPHARMA HOLDINGS INC (XERS) 7.7% 8.7% +1.0 pts −323K sh −10%
Reduced BIOCRYST PHARMACEUTICALS INC (BCRX) 3.6% 2.7% −0.9 pts −202K sh −22%
Exited LIPOCINE INC (LPCN) 0.7% — −0.7 pts −222K sh −100%
Increased TALPHERA INC (TLPH) 1.0% 2.0% +1.0 pts +1.82M sh +54%
Increased REGENTIS BIOMATERIALS LTD (RGNT) 0.3% 0.9% +0.6 pts +450K sh +179%
Reduced ONKURE THERAPEUTICS INC (OKUR) 0.8% 0.3% −0.5 pts −294K sh −66%
Increased NEURAXIS INC (NRXS) 0.7% 1.1% +0.4 pts +222K sh +78%
Exited AVALO THERAPEUTICS INC (AVTX) 0.5% — −0.5 pts −75,000 sh −100%
Exited ANNEXON INC (ANNX) 0.5% — −0.5 pts −200K sh −100%
New SPRUCE BIOSCIENCES INC (SPRB) — 0.4% +0.4 pts +20,000 sh new
Reduced POLYPID LTD (PYPD) 1.1% 0.7% −0.3 pts −208K sh −35%
Reduced VOR BIOPHARMA INC (VOR) 5.1% 4.5% −0.6 pts −51,400 sh −7%
Reduced EYEPOINT PHARMACEUTICALS INC (EYPT) 5.5% 5.3% −0.2 pts −48,507 sh −5%
New PEPGEN INC (PEPG) — 0.2% +0.2 pts +350K sh new
Reduced ATEA PHARMACEUTICALS INC (AVIR) 2.6% 1.9% −0.7 pts −101K sh −9%
Reduced MYOMO INC (MYO) 1.1% 1.4% +0.4 pts −209K sh −5%
Reduced SAVARA INC (SVRA) 7.2% 7.4% +0.2 pts −25,600 sh −1%
Increased BIOFRONTERA INC (BFRI) 0.4% 0.5% +0.1 pts +112K sh +10%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 74.9% of the equity book

Changes in the top 10 this quarter: CYBN entered · MDWD left

# Security Weight before Weight now
1 DELCATH SYSTEMS, INC. (DCTH) 12.5% 15.6%
2 FENNEC PHARMACEUTICALS INC (FENC) 7.3% 12.9%
3 XERIS BIOPHARMA HOLDINGS INC (XERS) 7.7% 8.7%
4 SAVARA INC (SVRA) 7.2% 7.4%
5 VERASTEM INC (VSTM) 4.6% 5.7%
6 X4 PHARMACEUTICALS INC (XFOR) 5.4% 5.6%
7 EYEPOINT PHARMACEUTICALS INC (EYPT) 5.5% 5.3%
8 CYBIN INC (CYBN) 3.0% 4.9% Entered the top 10
9 VOR BIOPHARMA INC (VOR) 5.1% 4.5%
10 VAXCYTE INC (PCVX) 6.9% 4.4%
— MEDIWOUND LTD (MDWD) 4.9% 4.1% Left the top 10

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).

Option positions (puts and calls)

Reported separately from the positions above. The value a 13F reports for an option is that of the underlying shares, not the option itself.

Activity Security Type Shares before Shares now Reported value
Exited REPLIMUNE GROUP INC (REPL) Call 1.28M 0 $0
New SELLAS LIFE SCIENCES GROUP INC (SLS) Put 0 569K $2.3M
Exited INVESCO QQQ TR (QQQ) Put 250K 0 $0
Exited SPDR S&P 500 ETF TR (SPY) Put 125K 0 $0
New CG ONCOLOGY INC (CGON) Call 0 31,000 $375K
New EYEPOINT PHARMACEUTICALS INC (EYPT) Call 0 50,300 $131K
New ISHARES TR (NYC) Put 0 500K $110K
Exited VIRIDIAN THERAPEUTICS INC (VRDN) Put 264K 0 $0
New SPDR SERIES TRUST (BIL) Put 0 141K $35.2K
New TENAX THERAPEUTICS INC (TENX) Put 0 6,200 $14K
Exited UNIQURE NV (QURE) Call 296K 0 $0
Exited ARRIVENT BIOPHARMA INC (AVBP) Call 109K 0 $0